The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | SWOG S0016: MRD status predicts outcomes of chemoimmunotherapy in patients with FL
In this video, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the predictive value of measurable residual disease (MRD) status for patients with follicular lymphoma (FL) undergoing chemoimmunotherapy (CIT). MRD analysis using the ClonoSeq assay successfully predicted improved progression-free survival (PFS) in the SWOG S0016 trial (NCT00006721). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: MEI, Lilly Oncology, Nurix, Abbvie, Beigene, Janssen, Astra Zeneca, Bristol Meyers Squibb, Genentech, GenMab, Merck
Research Funding: MEI, Lilly Oncology, Cyclacel, Bayer, Nurix, Abbvie, Beigene, Astra Zeneca, Bristol Meyers Squibb, GenMab
